Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arena Pharmaceuticals, Inc. (NASDAQ: ARNA).

Full DD Report for ARNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARNA)

Bank of America Merrill Lynch Healthcare Conference
The following slide deck was published by Arena Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 17 2018 20:06
Arena Pharmaceuticals' (ARNA) CEO Amit Munshi presents at Bank of America Merrill Lynch Healthcare Brokers Conference (Transcript)
Arena Pharmaceuticals, Inc. (ARNA) Bank of America Merrill Lynch Healthcare Brokers Conference May 18, 2017 14:35 ET Executives Amit Munshi - President and CEO Analysts Presentation Amit Munshi We've got about 15 minutes, I will move fairly rapidly through the slides. T...
Source: SeekingAlpha
Date: May, 17 2018 20:00
My 2 Cents On The Ozanimod Saga
There has been much written about the decline in Celgene (CELG) share price over the last 6 months. The recent refuse to file (RTF) letter from the FDA for ozanimod's NDA has added to the controversy over Celgene's prospects and management competence. In this article, I don’t try to elu...
Source: SeekingAlpha
Date: May, 15 2018 08:30
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot Barn, and Green Dot - Future Expectations, Projections Moving into 2018
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Haemonetics Corporation (NYSE:HAE), Arena Pharmaceuticals, Inc. (NASDAQ:AR...
Source: GlobeNewswire
Date: May, 15 2018 08:10
Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q1 2018 Results - Earnings Call Transcript
Arena Pharmaceuticals, Inc. (ARNA) Q1 2018 Earnings Conference Call May 08, 2018 04:30 PM ET Executives Kevin Lind - Chief Financial Officer Amit Munshi - President and Chief Executive Officer Analysts Martin Auster - Credit Suisse Jason Butler - JMP Securities Joseph Sch...
Source: SeekingAlpha
Date: May, 14 2018 21:44
Arena Reports Q1 Earnings - Loss Of $32 Million, Critical Etrasimod Update
Arena Pharmaceuticals ( ARNA ) reported its Q1 earnings on May 8th after the market closed. The company announced a loss of $32 million for the quarter, or about ($0.80) per share. A loss was expected, as the company is in full fledged research and development mode more-so than in a revenue ...
Source: SeekingAlpha
Date: May, 09 2018 06:31
Arena Pharmaceuticals misses by $0.10, misses on revenue
Arena Pharmaceuticals (NASDAQ: ARNA ): Q1 EPS of -$0.78 misses by $0.10 . More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:04
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN DIEGO , May 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2018 . "After delivering positive Phase 2 data on our most advanced compounds, etrasimod and ...
Source: PR Newswire
Date: May, 08 2018 16:01
Celgene Beats The Street On Earnings, But Big Worry Was Ozanimod
Celgene ( CELG ) was under a lot of pressure to put up a good earnings report. After one of its lead pipeline drugs, Ozanimod, got a snub from the FDA recently, the company needed to put some good news onto the proverbial table. On its Q1 conference call, the company was able to calm the water...
Source: SeekingAlpha
Date: May, 05 2018 06:46

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1336.7836.9137.1336.2056218,715
2018-08-1037.2436.6738.0336.62448,782
2018-08-0937.5637.5439.3537.275567,529
2018-08-0836.1237.6838.1036.07924,325
2018-08-0738.2536.4938.4134.901,142,066

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1325,41962,87840.4259Short
2018-08-1035,279101,96334.5998Cover
2018-08-0976,050189,14340.2077Short
2018-08-0885,341350,01024.3824Cover
2018-08-07123,137431,49828.5371Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARNA.


About Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

Logo for Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

Not available

 

Contact Information

 

 

Current Management

  • Jack Leif / President, CEO

Current Share Structure

  • Market Cap: $1,797,509,340 - 05/14/2018
  • Issue and Outstanding: 39,401,783 - 03/09/2018

 


Recent Filings from (NASDAQ: ARNA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018

 

 


Daily Technical Chart for (NASDAQ: ARNA)

Daily Technical Chart for (NASDAQ: ARNA)


Stay tuned for daily updates and more on (NASDAQ: ARNA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ARNA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ARNA and does not buy, sell, or trade any shares of ARNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/